Arcturus Therapeutics Holdings Inc (ARCT)

Currency in USD
7.28
+0.39(+5.66%)
Closed·
7.35+0.07(+0.96%)
·
Unusual trading volume
ARCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.268.28
52 wk Range
5.8524.17
Key Statistics
Prev. Close
6.89
Open
7.32
Day's Range
7.26-8.28
52 wk Range
5.85-24.17
Volume
1.91M
Average Volume (3m)
433.22K
1-Year Change
-47.1698%
Book Value / Share
6.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.60
Upside
+182.97%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings upwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 20.60
(+182.97% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Freedom Broker
Buy27.00+270.88%-New CoverageJul 02, 2026
B.Riley
Buy22.00+202.20%-New CoverageMar 18, 2026
Canaccord
Buy21.00+188.46%66.00MaintainMar 05, 2026
Citi
Hold8.00+9.89%7.00MaintainMar 04, 2026
Roth/MKM
Buy20.00+174.73%-New CoverageJan 23, 2026

Arcturus Therapeutics Holdings Inc SWOT Analysis


mRNA Trailblaze
Arcturus Therapeutics leads with self-amplifying mRNA technology, potentially revolutionizing vaccine efficacy and safety profiles in a competitive market
Financial Trajectory
Explore Arcturus' path to profitability, balancing strong liquidity with negative margins as it aims to capitalize on its innovative pipeline
Strategic Alliances
Delve into Arcturus' partnership with CSL Seqirus, offering billions in potential milestones and global market access for its vaccine candidates
Market Opportunities
Analyst targets range from $41 to $140, reflecting diverse views on Arcturus' potential in COVID-19, influenza, and emerging vaccine markets
Read full SWOT analysis

Arcturus Therapeutics Holdings Inc Earnings Call Summary for Q1/2026

  • Arcturus reported Q1 2026 EPS of -$0.95, beating analyst estimates of -$1.12 by 15.18% through effective cost management.
  • Revenue declined to $2.06M year-over-year due to strategic pivot from partnership income toward proprietary rare disease programs.
  • Strong cash position of $213.4M extends operational runway through Q2 2028, supporting mRNA therapeutic pipeline development.
  • Stock rose modestly 0.22% to $9.15 in aftermarket trading, remaining near 52-week lows despite EPS beat.
  • Management expects revenue growth as rare disease programs advance, targeting key clinical and regulatory milestones by end of 2026.
Last Updated: 2026-05-07, 08:44 p/m
Read Full Transcript

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-0.95 / -1.12
Revenue / Forecast
2.06M / --
EPS Revisions
Last 90 days

ARCT Income Statement

Compare ARCT to Peers and Sector

Metrics to compare
ARCT
Peers
Sector
Relationship
P/E Ratio
−2.6x−3.3x−0.4x
PEG Ratio
0.21−0.050.00
Price/Book
1.1x1.8x2.6x
Price / LTM Sales
3.8x11.6x3.0x
Upside (Analyst Target)
181.6%94.8%49.1%
Fair Value Upside
Unlock−4.3%6.1%Unlock

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
13.65M48.02%99.36M
Other Institutional Investors
9.07M31.92%66.04M
Public Companies & Retail Investors
5.70M20.07%41.52M
Total
28.42M100.00%206.92M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Federated Hermes, Inc.11.62%3,303,64024,050
ARK Investment Management LLC10.37%2,947,55621,458

People Also Watch

11.620
ABSI
+4.59%
1.3600
GERN
+7.09%
11.58
REPL
+3.21%
244.31
AXSM
+1.52%
555.91
UTHR
+1.60%

FAQ

What Is the Arcturus Therapeutics Holdings Inc (ARCT) Stock Price Today?

The Arcturus Therapeutics Holdings Inc stock price today is 7.28 USD.

What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?

Arcturus Therapeutics Holdings Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?

The stock symbol for Arcturus Therapeutics Holdings Inc is "ARCT."

What Is the Arcturus Therapeutics Holdings Inc Market Cap?

As of today, Arcturus Therapeutics Holdings Inc market cap is 206.92M USD.

What Is Arcturus Therapeutics Holdings Inc's Earnings Per Share (TTM)?

The Arcturus Therapeutics Holdings Inc EPS (TTM) is -2.84.

When Is the Next Arcturus Therapeutics Holdings Inc Earnings Date?

Arcturus Therapeutics Holdings Inc will release its next earnings report on Aug 10, 2026.

From a Technical Analysis Perspective, Is ARCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Arcturus Therapeutics Holdings Inc Stock Split?

Arcturus Therapeutics Holdings Inc has split 1 times.

How Many Employees Does Arcturus Therapeutics Holdings Inc Have?

Arcturus Therapeutics Holdings Inc has 109 employees.

What is the current trading status of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Jul 05, 2026, Arcturus Therapeutics Holdings Inc (ARCT) is trading at a price of 7.28 USD, with a previous close of 6.89 USD. The stock has fluctuated within a day range of 7.26 USD to 8.28 USD, while its 52-week range spans from 5.85 USD to 24.17 USD.

What Is Arcturus Therapeutics Holdings Inc (ARCT) Price Target According to Analysts?

The average 12-month price target for Arcturus Therapeutics Holdings Inc is 20.60 USD, with a high estimate of 40 USD and a low estimate of 8 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +182.97% Upside potential.

What Is the ARCT After Hours Price?

ARCT's last after hours stock price is 7.35 USD, the stock has decreased by 0.07, or 0.96%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.